Biocon Biologics gets USFDA approval for Jobevne cancer drug

research chemistry medicine product at science lab
| Photo Credit:
Artsanova

Biocon Biologics, the biosimilar arm of Biocon has expanded its oncology portfolio with the USFDA approval of Jobevne, a cancer treatment drug.

Jobevne is a biosimilar version of Bevacizumab (marketed as Avastin), a monoclonal antibody used in combination with chemotherapy to treat several types of cancer, including colorectal, lung, brain, kidney, and cervical cancers. The drug is administered through intravenous infusion.

With this approval, Jobevne becomes the company’s fourth oncology biosimilar in the US, adding to its existing portfolio that includes OGIVRI (trastuzumab), FULPHILA (pegfilgrastim), and ABEVMY (another bevacizumab biosimilar approved in other markets). Bevacizumab sales in the US stood at around $2 billion in 2023.

“Jobevne is our seventh biosimilar approved in the US and a strong addition to our oncology portfolio. We look forward to working with all stakeholders to bring more treatment options to patients,” said Shreehas Tambe, CEO & Managing Director of Biocon Biologics Ltd.

The US market contributes 40 per cent to Biocon Biologics’ overall revenue. The company currently has 20 biosimilars in its development pipeline, including insulins and monoclonal antibodies across various therapies. In addition to its US focus, Biocon Biologics is seeing growth in markets like Japan and Australia through its commercial partners, noted Tambe in an earlier conversation with businessline.

In the third quarter that ended in December 2024, the company’s biosimilars segment posted revenue of ₹2,289 crore, up 14 per cent year-on-year on a like-for-like basis. Profits rose 5 per cent sequentially. Research and development spending stood at ₹135 crore. The oncology segment saw strong demand during the quarter, while insulin sales remained in the mid-to-high teens across all distribution channels.

More Like This

Published on April 10, 2025